THU126 SARS-CoV-2 Infection And Vaccination In Patients With Pituitary Diseases: A Pilot Study
Abstract
Abstract Disclosure: M.C. Silva: None. L.M. Del Corso: None. C.L. Boguszewski: None. Introduction: The COVID-19 pandemic caused by the SARS-CoV-2 virus brought several questions globally. Among patients with pituitary diseases, there are few data in the literature about prevalence of SARS-CoV-2 infection, vaccination and their possible consequences and adverse events. Aim: To evaluate the prevalence and characteristics of SARS-CoV-2 infection, and the prevalence, efficacy and safety of vaccination in adult patients with pituitary diseases. Methods: Observational, cross-sectional study of adult patients with pituitary diseases followed in a reference center. Clinical data were collected and a questionnaire about SARS-CoV-2 infection, vaccination and its possible adverse effects was applied. The severity definitions used for COVID-19 disease were based on the World Health Organization: Mild – symptoms of infection without pneumonia; Moderate – presence of pneumonia; Severe – severe pneumonia (respiratory rate greater than 30 breaths per minute, severe respiratory distress or oxygen saturation less than 90% on room air). Results: We have studied 116 consecutive patients, 59 women (50.9%), with a median age of 47.5 years (range 39-59). The cause of pituitary disease was tumoral in 82 cases (70.7%) and non-tumoral in 34 (29.3%), the most prevalent etiologies were prolactinoma (n=31; 26.7%), idiopathic hypopituitarism (n=30; 25.9%) and acromegaly (n=23; 19.8%). Among hypopituitary…
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 116 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.